Astellas Pharma (4503) 주식 개요
는 일본 및 국제적으로 의약품을 제조, 판매, 수출입하는 회사입니다. 자세히 보기
4503 Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Astellas Pharma Inc. 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | JP¥2,363.00 |
| 52주 최고가 | JP¥2,717.00 |
| 52주 최저가 | JP¥1,557.50 |
| 베타 | 0.081 |
| 1개월 변동 | 10.32% |
| 3개월 변동 | 1.50% |
| 1년 변동 | 46.27% |
| 3년 변동 | 6.25% |
| 5년 변동 | 35.26% |
| IPO 이후 변동 | 301.87% |
최근 뉴스 및 업데이트
분석 기사 • Aug 08
Astellas Pharma Inc. Just Recorded A 55% EPS Beat: Here's What Analysts Are Forecasting Next
A week ago, Astellas Pharma Inc. ( TSE:4503 ) came out with a strong set of first-quarter numbers that could...
내러티브 업데이트 • Aug 05
4503: Oncology Approvals And Trial Updates Will Drive Future Upside Potential
Analysts have raised their price target for Astellas Pharma from ¥2,950 to about ¥3,098, reflecting updated assumptions around slightly less revenue decline, a modestly lower profit margin, and a higher future P/E multiple. What's in the News Astellas Pharma and Pfizer received U.S. FDA approval for PADCEV plus Keytruda or Keytruda QLEX as neoadjuvant and adjuvant treatment for adult patients with muscle invasive bladder cancer, regardless of cisplatin eligibility, based on Phase 3 EV-304 data presented at the 2026 ASCO Genitourinary Cancers Symposium.Recent updates
분석 기사 • Aug 08
Astellas Pharma Inc. Just Recorded A 55% EPS Beat: Here's What Analysts Are Forecasting Next
A week ago, Astellas Pharma Inc. ( TSE:4503 ) came out with a strong set of first-quarter numbers that could...내러티브 업데이트 • Aug 05
4503: Oncology Approvals And Trial Updates Will Drive Future Upside Potential
Analysts have raised their price target for Astellas Pharma from ¥2,950 to about ¥3,098, reflecting updated assumptions around slightly less revenue decline, a modestly lower profit margin, and a higher future P/E multiple. What's in the News Astellas Pharma and Pfizer received U.S. FDA approval for PADCEV plus Keytruda or Keytruda QLEX as neoadjuvant and adjuvant treatment for adult patients with muscle invasive bladder cancer, regardless of cisplatin eligibility, based on Phase 3 EV-304 data presented at the 2026 ASCO Genitourinary Cancers Symposium.분석 기사 • Jun 23
Astellas Pharma's (TSE:4503) Earnings May Just Be The Starting Point
Even though Astellas Pharma Inc.'s ( TSE:4503 ) recent earnings release was robust, the market didn't seem to notice...
내러티브 업데이트 • Jun 23
4503: KRAS Oncology And AI Overhaul Will Likely Strain Future Returns
The latest analyst update on Astellas Pharma edges the fair value estimate from ¥1,669.63 to ¥1,701.65, with the modest change tied to revised assumptions on revenue trends, profit margins, and projected future P/E levels. What’s in the News for Astellas Pharma Astellas Pharma is internalizing clinical operations and adopting artificial intelligence tools in drug development, with a focus on improving clinical trial efficiency and decision making.내러티브 업데이트 • Jun 07
4503: CSP2026 Oncology Pipeline And Dividends Will Drive Future Upside Potential
Analysts are holding their ¥2,950 price target for Astellas Pharma, with updated assumptions indicating softer revenue growth, higher profit margins, and a lower future P/E, which together help support the unchanged valuation. What's in the News Astellas announced its five year Corporate Strategic Plan "CSP2026," targeting 10 or more Phase 3 or pivotal studies by fiscal 2030 and aiming to double revenue from its Strategic Brands, with an objective of record high revenue in the mid 2030s and ongoing annual dividend increases (source: Astellas CSP2026 announcement).내러티브 업데이트 • May 24
4503: Rising Bladder Cancer Setback Risks Will Likely Pressure Future Returns
Astellas Pharma's analyst price target has shifted from a fair value of ¥1,500 to about ¥1,670 as analysts factor in a higher assumed discount rate, softer revenue and profit expectations, and a higher future P/E multiple in their updated models. What's in the News Astellas plans to present new data across its oncology portfolio at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago, including a 3.5-year follow up from the Phase 3 EV-302 study of enfortumab vedotin plus pembrolizumab in previously untreated locally advanced or metastatic urothelial cancer, along with multiple prostate cancer and vasomotor symptom studies.
내러티브 업데이트 • May 02
4503: Bladder Cancer Progress And Updated Guidance Will Shape Fairly Balanced Outlook
Analysts have slightly reduced their fair value estimate for Astellas Pharma from about ¥2,407 to about ¥2,396, citing updated assumptions that include a softer revenue outlook, a higher projected profit margin, and a lower future P/E multiple. What's in the News Astellas and Pfizer reported positive Phase 3 EV-304 data for PADCEV (enfortumab vedotin) plus Keytruda (pembrolizumab) in muscle invasive bladder cancer, with the regimen linked to a 47% lower risk of tumor recurrence, progression or death and a 35% lower risk of death compared with standard chemotherapy, along with a higher pathological complete response rate and no new safety signals (Key Developments).분석 기사 • Apr 30
Astellas Pharma Inc. (TSE:4503) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?
Astellas Pharma Inc. ( TSE:4503 ) shareholders are probably feeling a little disappointed, since its shares fell 7.8...내러티브 업데이트 • Apr 17
4503: Bladder Cancer Data And Guidance Will Temper Risks From Weaker Legacy Portfolio
Analysts have nudged their fair value estimate for Astellas Pharma higher from ¥2,100 to about ¥2,407, citing updated assumptions for revenue trends, profit margins, and a slightly lower future P/E multiple. What's in the News Astellas and HOVON reported that the Phase 3 HOVON 156 / AMLSG 28-18 / PASHA study of XOSPATA (gilteritinib) versus midostaurin-based treatment in newly diagnosed FLT3-mutated acute myeloid leukemia did not meet its primary overall survival endpoint, with Astellas indicating it expects a minor impact on financial results for the fiscal year ending March 31, 2026 (Key Developments).내러티브 업데이트 • Apr 02
4503: Future Oncology Pipeline And Partnerships Will Support Upside Potential
The analyst price target for Astellas Pharma has been revised from ¥2,700 to ¥2,950, with analysts citing updated assumptions for revenue growth, profit margins, and a higher future P/E multiple as key drivers behind the change. What's in the News Phase 3 HOVON 156 / AMLSG 28-18 / PASHA trial of XOSPATA (gilteritinib) in newly diagnosed FLT3-mutated acute myeloid leukemia did not meet its primary overall survival endpoint, and Astellas plans a full data review and expects only a minor impact on fiscal 2026 results.내러티브 업데이트 • Mar 19
4503: Trial Setbacks And Weaker Margins Will Likely Pressure Future Returns
Analysts have kept Astellas Pharma's fair value estimate steady at ¥1,500, while slightly adjusting assumptions for discount rate, revenue growth, profit margin and future P/E to reflect updated views on the company’s risk profile and earnings power, without changing the overall price target level. What's in the News Phase 3 HOVON 156 / AMLSG 28-18 / PASHA trial of XOSPATA (gilteritinib) in newly diagnosed FLT3-mutated acute myeloid leukemia did not meet its primary overall survival endpoint.내러티브 업데이트 • Mar 05
4503: Bladder Cancer Pipeline Dependence Will Increase Execution Risk Versus Weakening Revenue Outlook
Astellas Pharma's analyst price target has been adjusted from ¥1,938 to ¥2,100, with analysts pointing to updated assumptions around a slightly higher discount rate, softer revenue growth, a modestly stronger profit margin and a higher future P/E multiple to support the new view. What's in the News Pfizer and Astellas reported positive Phase 3 EV-304 results for PADCEV in combination with Keytruda in muscle invasive bladder cancer.내러티브 업데이트 • Feb 19
4503: Revised Earnings Outlook And Clinical Progress Will Support Balanced Future Upside
Analysts have adjusted their view on Astellas Pharma, raising the price target from ¥2,400 to ¥2,700, citing revised assumptions for the discount rate, revenue growth, profit margin, and future P/E. What's in the News Astellas revised its consolidated earnings guidance for the fiscal year ending March 31, 2026, now forecasting core revenue of ¥2,100,000 million, operating profit of ¥520,000 million, profit for the year of ¥385,000 million, and basic EPS of ¥214.95, with similar revisions on a full basis.분석 기사 • Feb 08
Astellas Pharma Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Astellas Pharma Inc. ( TSE:4503 ) defied analyst predictions to release its quarterly results, which were ahead of...내러티브 업데이트 • Feb 05
4503: Elevated Earnings Outlook Will Likely Mask Higher Long Term Margin Risks
Analysts have increased their fair value estimate for Astellas Pharma from ¥1,300 to ¥1,500, citing updated assumptions that include a revised revenue growth profile, higher projected profit margins, and a lower anticipated future P/E multiple. What's in the News Astellas raised its consolidated earnings guidance for the fiscal year ending March 31, 2026, now forecasting core revenue of ¥2,100,000 million, operating profit of ¥520,000 million, profit for the year of ¥385,000 million, and basic EPS of ¥214.95, supported by XTANDI and mirabegron products and foreign exchange effects (Key Developments).분석 기사 • Feb 05
Astellas Pharma (TSE:4503) Has Announced A Dividend Of ¥39.00
The board of Astellas Pharma Inc. ( TSE:4503 ) has announced that it will pay a dividend of ¥39.00 per share on the 3rd...내러티브 업데이트 • Jan 22
4503: Rising Bladder Cancer Reliance Will Increase Execution Risk Versus Softer Revenue Outlook
Analysts have nudged their fair value estimate for Astellas Pharma up from ¥1,884.62 to ¥1,938.46, citing updated assumptions around slightly softer revenue growth, a modestly higher profit margin, and a small adjustment to the future P/E multiple. What's in the News Sanofi is reported to be preparing a higher bid for Ocular Therapeutix, which keeps attention on deal activity in ophthalmology and broader specialty pharma (Investor's Business Daily).분석 기사 • Jan 19
Astellas Pharma's (TSE:4503) Dividend Will Be ¥39.00
The board of Astellas Pharma Inc. ( TSE:4503 ) has announced that it will pay a dividend on the 3rd of June, with...내러티브 업데이트 • Jan 07
4503: Rising Bladder Cancer Pipeline Reliance Will Increase Execution And Partnering Risks
Analysts have modestly raised their fair value estimate for Astellas Pharma from ¥1,792.14 to ¥1,884.62, citing updated assumptions around slightly softer revenue contraction, a higher profit margin outlook, and a small adjustment to the future P/E multiple. What's in the News The U.S. FDA approved PADCEV in combination with Keytruda as perioperative treatment for adult patients with muscle invasive bladder cancer who are ineligible for cisplatin chemotherapy.분석 기사 • Jan 05
Astellas Pharma's (TSE:4503) Dividend Will Be ¥39.00
Astellas Pharma Inc. ( TSE:4503 ) will pay a dividend of ¥39.00 on the 3rd of June. This makes the dividend yield 3.7...분석 기사 • Dec 17
Astellas Pharma (TSE:4503) Will Pay A Dividend Of ¥39.00
The board of Astellas Pharma Inc. ( TSE:4503 ) has announced that it will pay a dividend of ¥39.00 per share on the 3rd...내러티브 업데이트 • Dec 14
4503: Early Veeva CRM Adoption Will Support Margin Expansion And Upside Potential
Analysts have nudged their price target on Astellas Pharma higher from ¥2,200 to ¥2,400, citing the company’s role among leading pharma adopters of Veeva’s upgraded CRM platform and a modestly improved long term profit margin outlook, despite slightly softer revenue growth assumptions. Analyst Commentary Bullish analysts point to Astellas Pharma’s early adoption of Veeva’s Vault CRM as a key validation of its digital commercial strategy, aligning the company with a growing roster of large global biopharma peers migrating to the upgraded platform.분석 기사 • Dec 03
Astellas Pharma (TSE:4503) Will Pay A Dividend Of ¥39.00
Astellas Pharma Inc. ( TSE:4503 ) has announced that it will pay a dividend of ¥39.00 per share on the 3rd of June...내러티브 업데이트 • Nov 29
4503: Major Partner Platform Commitments Will Shape Competitive Positioning And Execution Risks
Analysts have slightly raised their price target for Astellas Pharma to ¥1,792.14 from ¥1,774.29. They cite continued incremental commitments from major industry partners as a supportive factor for the company's outlook.내러티브 업데이트 • Nov 15
4503: Digital Transformation Commitments Will Drive Operational Efficiency And Execution Risk Ahead
Astellas Pharma's fair value target has been raised slightly from ¥1,753 to ¥1,774. This reflects analysts' expectations of improved revenue and margin trends in light of a renewed commitment to digital transformation within the sector.분석 기사 • Nov 07
Astellas Pharma's (TSE:4503) Earnings May Just Be The Starting Point
When companies post strong earnings, the stock generally performs well, just like Astellas Pharma Inc.'s ( TSE:4503...분석 기사 • Nov 03
Astellas Pharma Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
As you might know, Astellas Pharma Inc. ( TSE:4503 ) just kicked off its latest half-yearly results with some very...내러티브 업데이트 • Nov 01
4503: Digital CRM Adoption And Margin Pressures Will Shape Medium-Term Performance
Analysts have revised their price target for Astellas Pharma to ¥1,752.86, citing a more cautious outlook on revenue growth and margin pressures. This update reflects recent industry research and changes in competitive dynamics.내러티브 업데이트 • Oct 17
Oncology And Rare Diseases Trends Will Unlock Global Potential
Astellas Pharma's analyst price target has increased slightly from ¥1,749.29 to ¥1,752.86. Analysts cite ongoing partnerships with industry leaders and an improved outlook on core platform adoption as contributing factors.내러티브 업데이트 • Oct 03
Oncology And Rare Diseases Trends Will Unlock Global Potential
Analysts have raised their price target for Astellas Pharma from ¥1,725 to ¥1,749, citing steady fundamentals and ongoing industry commitments. These points were highlighted in recent sector developments.분석 기사 • Sep 19
Astellas Pharma's (TSE:4503) Upcoming Dividend Will Be Larger Than Last Year's
Astellas Pharma Inc. ( TSE:4503 ) has announced that it will be increasing its dividend from last year's comparable...내러티브 업데이트 • Sep 18
Oncology And Rare Diseases Trends Will Unlock Global Potential
Despite a further decline in consensus revenue growth forecasts, Astellas Pharma’s analyst price target inched up from ¥1708 to ¥1725, reflecting only a marginal increase in perceived fair value. What's in the News Positive Phase 3 results for PADCEV (enfortumab vedotin) plus KEYTRUDA (pembrolizumab) in muscle-invasive bladder cancer (MIBC) patients ineligible for cisplatin; significant improvement in event-free and overall survival compared to surgery alone, with consistent safety profiles.내러티브 업데이트 • Aug 27
Oncology And Rare Diseases Trends Will Unlock Global Potential
Despite a notable improvement in consensus revenue growth forecasts, Astellas Pharma’s fair value was revised only slightly lower, with the analyst price target decreasing marginally from ¥1711 to ¥1692. What's in the News Positive Phase 3 EV-303 trial results for PADCEV (enfortumab vedotin) plus KEYTRUDA (pembrolizumab) in muscle-invasive bladder cancer show clinically meaningful improvements in event-free and overall survival versus surgery alone.분석 기사 • Aug 12
Astellas Pharma's (TSE:4503) Upcoming Dividend Will Be Larger Than Last Year's
Astellas Pharma Inc. ( TSE:4503 ) has announced that it will be increasing its dividend from last year's comparable...주주 수익률
| 4503 | JP Pharmaceuticals | JP 시장 | |
|---|---|---|---|
| 7D | 8.6% | 5.7% | 3.3% |
| 1Y | 46.3% | 17.8% | 34.3% |
수익률 대 산업: 4503은 지난 1년 동안 17.8%의 수익을 기록한 JP Pharmaceuticals 산업보다 더 좋은 성과를 냈습니다.
수익률 대 시장: 4503은 지난 1년 동안 34.3%를 기록한 JP 시장보다 더 좋은 성과를 냈습니다.
주가 변동성
| 4503 volatility | |
|---|---|
| 4503 Average Weekly Movement | 4.3% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in JP Market | 9.4% |
| 10% least volatile stocks in JP Market | 2.2% |
안정적인 주가: 4503는 지난 3개월 동안 JP 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: 4503의 주간 변동성(4%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 1923 | 14,099 | Naoki Okamura | www.astellas.com |
는 일본 및 해외에서 의약품을 제조, 판매, 수출입하는 기업입니다. 이 회사는 전립선암 치료제인 엑스탄디, FLT3 변이가 있는 재발성 또는 불응성 급성 골수성 백혈병 환자 치료제인 조스파타, 전이성 요로상피암 환자 치료제인 패드세브 등을 공급하고 있습니다. 또한 만성 신장 질환과 관련된 빈혈 치료제인 에브렌조, 과민성 방광 치료제인 베타니스/미라베트릭/베트미가, 면역 억제제인 프로그라프와 애드바그라프/그레이스펙터/아스타그라프 XL을 제공하고 있습니다.
Astellas Pharma Inc. 기초 지표 요약
| 4503 기초 통계 | |
|---|---|
| 시가총액 | JP¥4.24t |
| 순이익 (TTM) | JP¥364.94b |
| 매출 (TTM) | JP¥2.27t |
11.6x
주가수익비율(P/E)1.9x
주가매출비율(P/S)4503는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| 4503 손익계산서 (TTM) | |
|---|---|
| 매출 | JP¥2.27t |
| 매출원가 | JP¥436.30b |
| 총이익 | JP¥1.84t |
| 기타 비용 | JP¥1.47t |
| 순이익 | JP¥364.94b |
최근 보고된 실적
Jun 30, 2026
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | 203.53 |
| 총이익률 | 80.82% |
| 순이익률 | 16.05% |
| 부채/자본 비율 | 30.3% |
4503의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기| Astellas Pharma 배당 일정 | |
|---|---|
| 배당락일 | Sep 29 2026 |
| 배당 지급일 | Dec 01 2026 |
| 배당락일까지 남은 일수 | 49 days |
| 배당 지급일까지 남은 일수 | 112 days |
4503는 안정적으로 배당을 지급합니까?
4503 배당 기록 및 벤치마크 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/08/10 05:23 |
| 종가 | 2026/08/10 00:00 |
| 수익 | 2026/06/30 |
| 연간 수익 | 2026/03/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Astellas Pharma Inc.는 24명의 분석가가 다루고 있습니다. 이 중 12명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Atsushi Seki | Barclays |
| Miki Sogi | Bernstein |
| Koichi Mamegano | BofA Global Research |